Precision medicine: Sustained response to erdafitinib in FGFR2‐mutant, multiply recurrent ameloblastoma

Abstract Background Ameloblastoma imposes significant morbidity and high‐recurrence rates following surgery and radiation therapy. Although 89% of cases harbor oncogenic mutations, the role of targeted therapy is undefined. Case We describe a case of a 40‐year‐old male with multiply recurrent, local...

Descripció completa

Dades bibliogràfiques

Autors principals:	Katherine A. Lawson‐Michod, Christopher H. Le, Ghassan Tranesh, Penelope C. Thomas, Julie E. Bauman
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2022-10-01
Col·lecció:	Cancer Reports
Matèries:	ameloblastoma erdafitinib FGFR2 mutation precision medicine targeted therapy
Accés en línia:	https://doi.org/10.1002/cnr2.1656
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!